Resultados de procura - Toshio Takagi
- Mostrando 1 - 15 Resultados de 15
-
1
Subunit structure of soybean 11S globulin. por Keisuke Kitamura, Toshio Takagi, Kazuo Shibasaki
Publicado 1976Artigo -
2
-
3
-
4
-
5
-
6
Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma--Comparison to Standard Dosing Schedul... por T. Kondo, Toshio Takagi, Hirohito Kobayashi, J. Iizuka, Taiji Nozaki, Y. Hashimoto, Eri Ikezawa, Kazuhiko Yoshida, Kenji Omae, K. Tanabe
Publicado 2014Artigo -
7
-
8
Early unclamping might reduce the risk of renal artery pseudoaneurysm after robot-assisted laparoscopic partial nephrectomy por Tsunenori Kondo, Toshio Takagi, Satoru Morita, Kenji Omae, Yasunobu Hashimoto, Hirohito Kobayashi, Junpei Iizuka, Kazuhiko Yoshida, Norihiro Fukuda, Kazunari Tanabe
Publicado 2015Artigo -
9
Template‐based lymphadenectomy in urothelial carcinoma of the renal pelvis: A prospective study por Tsunenori Kondo, Isao Hara, Toshio Takagi, Yoshiki Kodama, Yasunobu Hashimoto, Hirohito Kobayashi, Junpei Iizuka, Kenji Omae, Kazuhiko Yoshida, Kazunari Tanabe
Publicado 2013Artigo -
10
Comparing surgical outcomes between robot-assisted laparoscopic and open partial nephrectomy for allograft kidney tumors: a retrospective, single-center study por Taro Banno, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Toshihito Hirai, Kazuya Omoto, Junpei Iizuka, Tomokazu Shimizu, Hideki Ishida, Toshio Takagi
Publicado 2025Artigo -
11
Acquired cystic disease‐associated renal cell carcinoma is the most common subtype in long‐term dialyzed patients: Central pathology results according to the 2016 WHO classificatio... por Tsunenori Kondo, Naoto Sasa, Hiroshi Yamada, Toshio Takagi, Junpei Iizuka, Hirohito Kobayashi, Kazuhiko Yoshida, Hironori Fukuda, Hiroki Ishihara, Kazunari Tanabe, Toyonori Tsuzuki
Publicado 2018Artigo -
12
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101 por Motohide Uemura, Yoshihiko Tomita, Hideaki Miyake, Shingo Hatakeyama, Hiro‐omi Kanayama, Kazuyuki Numakura, Toshio Takagi, Tomoyuki Kato, Masatoshi Eto, Wataru Obara, Hirotsugu Uemura, Toni K. Choueiri, Robert J. Motzer, Yosuke Fujii, Yoichi Kamei, Yoshiko Umeyama, Alessandra di Pietro, Mototsugu Oya
Publicado 2019Artigo -
13
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms por Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert J. Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung‐Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomáš Büchler, Toshio Takagi, Joseph E. Burgents, Rodolfo F. Perini, Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri
Publicado 2023Artigo -
14
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma por Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Publicado 2021Artigo -
15
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study por Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, B. Yа. Alekseev, Sun Young Rha, Jaime R. Merchan, Jeffrey C. Goh, Aly‐Khan A. Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung‐Hoo Hong, Howard Gurney, María José Méndez-Vidal, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso‐Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph E. Burgents, Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri, Robert J. Motzer, Toni K. Choueiri, Thomas E. Hutson, Luke T. Nordquist, David R. Spigel, Jaime R. Merchan, Saby George, Sandhya Srinivas, Brendan D. Curti, Andrew Pippas, Elisabeth I. Heath, Subramanya Rao, Theodore Stewart Gourdin, Mehmood Hashmi, Nafisa Burhani, Ana M. Molina, Alan J. Koletsky, Robert Alter, C. Alemany, Benjamin A. Gartrell, Mike Cusnir, Harsha Vyas, Stephanie L. Graff, Christian Squillante, Mark Knapp, Ivor Percent, Vijay Patel, Daniel L. Spitz, C. Harkness, Marc Matrana, Lindsay Overton, Stephen Richey, Donald Richards, Habib M. Ghaddar, Robert Galamaga, Ralph J. Hauke, Joseph Haggerty, Ronald Harris, Mark Johns, Samith T. Kochuparambil, Christian Kollmannsberger, Bobby Shayegan, Christina Canil, Eric Winquist, Catherine Sperlich, Georg A. Bjarnason, Naveen S. Basappa, Wolfgang Loidl, Wolfgang Horninger, Manuela Schmidinger, Lionel D’Hondt, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolická, Jiří Tomášek, Jana Prausová, Tomáš Büchler, Petra Holečková
Publicado 2024Artigo
Ferramentas de procura:
Materias Relacionadas
Medicine
Internal medicine
Cancer
Renal cell carcinoma
Oncology
Urology
Biology
Kidney
Nephrectomy
Sunitinib
Immunotherapy
Biochemistry
Lenvatinib
Pembrolizumab
Surgery
Adverse effect
Carcinoma
Chemistry
Computer science
Confidence interval
Enzyme
Everolimus
Gene
Hazard ratio
Hepatocellular carcinoma
Immunology
Kidney transplantation
Lymphadenectomy
Metastasis
Organic chemistry